PET scanning in lung cancer: Current status and future directions

Seminars in Surgical Oncology

Volumn 21, Issue 3, 2003, Pages 149-155

  Mac Manus, Michael P ^a   Hicks, Rodney J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Chemotherapy; Lung cancer; Positron emission tomography; Radiotherapy; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EVALUATION; FUTUROLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0141885242     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10032     Document Type: Review

References (46)

1. Kubota K: From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471-486.
2. Wahl RL, Hutchins GD, Buchsbaum DJ, et al: 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991;67:1544-1550.
3. Vesselle H, Schmidt RA, Pugsley JM, et al: Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-3844.
4. Chin R Jr, McCain TW, Miller AA, et al: Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002;37:1-6.
5. Gould MK, Maclean CC, Kuschner WG, et al: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-924.
6. Keith CJ, Miles KA, Griffiths MR, et al: Solitary pulmonary nodules: accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data. Eur J Nucl Med Mol Imaging 2002;29:1016-1023.
7. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-3206.
8. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-2149.
9. Wahl RL, Quint LE, Greenough RL, et al: Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-377.
10. Hany TF, Steinert HC, Goerres GW, et al: PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575-581.
11. Mac Manus MP, Hicks RJ, Ball DL, et al: F- 18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-895.
12. MacManus MP, Hicks RJ, Matthews JP, et al: High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-293.
13. Rosenman J: Incorporating functional imaging information into radiation treatment. Semin Radiat Oncol 2001;11:83-92.
14. Mac Manus MP, Matthews JP, McKenzie A, et al: Positron emission tomography is superior to CT scanning for response-assessment after radical radiotherapy/chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 2003.
15. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. Leuven Lung Cancer Group. Ann Oncol 1998;9:1193-1198.
16. Beyer T, Townsend DW, Blodgett TM: Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002;46:24-34.
17. Strauss GM: The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality. J Clin Oncol 2002;20:1973-1983.
18. Goo JM, Im JG, Do KH, et al: Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000;216:117-121.
19. Croft DR, Trapp J, Kernstine K, et al: FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002;36:297-301.
20. Bury T, Dowlati A, Paulus P, et al: Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410-414.
21. Fischer BM, Mortensen J, Hojgaard L: Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001;2:659-666.
22. Pitman AG, Hicks RJ, Kalff V, et al: Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. Med J Aust 2001;175:303-307.
23. Abou-Zied M, Zubeldia J, Nabi H: Follow-up of patients with single pulmonary nodules and negative 18F-fluorodeoxyglucose positron emission tomography scans. Clin Positron Imaging 2000;3:184.
24. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL: Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-536.
25. Hellwig D, Ukena D, Paulsen F, et al: [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. Pneumologie 2001;55:367-377.
26. Kernstine KH, McLaughlin KA, Menda Y, et al: Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg 2002;73:394-401; discussion 394-401.
27. van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359(9315):1388-1393.
28. Berlangieri SU, Scott AM: Metabolic staging of lung cancer. N Engl J Med 2000;343:290-292.
29. Mac Manus MP, Wong K, Hicks RJ, et al: Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 2002;52:351-361.
30. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350(9072): 161-165.
31. Eschmann SM, Friedel G, Paulsen F, et al: FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002;29:804-808.
32. Kiffer JD, Berlangieri SU, Scott AM, et al: The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998;19:167-177.
33. Erdi YE, Rosenzweig K, Erdi AK, et al: Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60.
34. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al: The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-324.
35. Nestle U, Walter K, Schmidt S, et al: 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593-597.
36. Ling CC, Humm J, Larson S, et al: Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-560.
37. Werner-Wasik M, Xiao Y, Pequignot E, et al: Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001;51:56-61.
38. Lever AM, Henderson D, Ellis DA, et al: Radiation fibrosis mimicking local recurrence in small cell carcinoma of the bronchus. Br J Radiol 1984;57:178 -180.
39. Choi NC, Fischman AJ, Niemierko A, et al: Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024-1035.
40. Erdi YE, Macapinlac H, Rosenzweig KE, et al: Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861-866.
41. Bury T, Corhay JL, Duysinx B, et al: Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14:1376-1380.
42. Hoekstra CJ, Hoekstra OS, Stroobants SG, et al: Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002;43:1304-1309.
43. Beyer T, Antoch G, Blodgett T, et al: Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003.
44. Shields AF, Grierson JR, Dohmen BM, et al: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-1336.
45. Buck AK, Schirrmeister H, Hetzel M, et al: 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for non-invasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-3334.
46. Kotzerke J, Gschwend JE, Neumaier B: PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med 2002;43:200-202.